Development of Software Support Tool for Planning Administration of Biapenem, a Carbapenem Antibacterial Agent, based on Pharmacokinetic/Pharmacodynamic Approach and Monte Carlo Simulation

In consideration of the proposal to base the rational use of biapenem, a carbapenem antibacterial agent, on pharmacokinetic/pharmacodynamic (PK/PD) theory, we created software to support the planning of biapenem administration based on a PK/PD approach using the Monte Carlo simulation. The software was created using a macro-program written in visual basic language for applications on Microsoft Excel. To predict values for the PK/PD parameters ‘time above the minimum inhibitory concentration (T>MIC)’ and probability of target attainment for approved biapenem dosage regimen against various bacteria populations, the Monte Carlo simulation was performed for 10000 subjects using the Crystal Ball® embedded pharmacokinetic program MULTI-Win. Variability in pharmacokinetic parameters and MIC distributions were obtained using OMEGACIN® package insert data and data from a nationwide antibiotics-susceptibility test surveillance program, respectively. When the software was used for a patient with severe pneumonia and renal failure who was undergoing haemodialysis, several dosage regimens were recommended based on T>MIC predicted from the patient's data, thereby demonstrating its clinical usefulness. Our software proved effective as a tool for supporting biapenem administration planning for individual patients, and rational use based on PK/PD theory concerning antimicrobial agents.

[1]  R. Ariano,et al.  Pharmacokinetics and Pharmacodynamics of Meropenem in Febrile Neutropenic Patients with Bacteremia , 2005, The Annals of pharmacotherapy.

[2]  C. Frei,et al.  Pharmacodynamic Analysis of Ceftriaxone, Gatifloxacin, and Levofloxacin Against Streptococcus pneumoniae with the Use of Monte Carlo Simulation , 2005, Pharmacotherapy.

[3]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[4]  G. Drusano,et al.  Pharmacodynamic Evaluation of Extending the Administration Time of Meropenem using a Monte Carlo Simulation , 2005, Antimicrobial Agents and Chemotherapy.

[5]  A. Shimizu,et al.  Optimization of dose and dose regimen of biapenem based on pharmacokinetic and pharmacodynamic analysis , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[6]  W. Craig,et al.  Animal model pharmacokinetics and pharmacodynamics: a critical review. , 2002, International journal of antimicrobial agents.

[7]  D. Nicolau,et al.  Comparison of Pharmacodynamic Target Attainment Between Healthy Subjects and Patients for Ceftazidime and Meropenem , 2005, Pharmacotherapy.

[8]  和朗 猪川,et al.  Microsoft Windows XP環境で使用可能な非線形最小二乗法に基づく薬物動態解析プログラム (MULTI-Win) の構築 , 2004 .

[9]  T Uematsu,et al.  Pharmacokinetics of a parenteral carbapenem, biapenem, in patients with end-stage renal disease and influence of haemodialysis. , 2000, The Journal of antimicrobial chemotherapy.